Discovery of a multicomponent alloy forged by the Hiroshima atomic blast
Summary
This Substack post argues that intelligence is not the main bottleneck to progress, especially in AI-enabled medicine, and that regulatory and governance obstacles are the real constraints. It surveys examples from pharmaceuticals and policy discussions to illustrate how data access, trial design, and incentives shape innovation, arguing for reforms over simply pursuing bigger AI capabilities. The piece also critiques a Silicon Valley monoculture around AGI and urges a more grounded view of what drives real-world impact.